Table 3.
Follow-up period and median progression-free and overall survival
| MPV3 (n = 23) | MTX5 (n = 15) | Log-rank test results | |
|---|---|---|---|
| Follow-up period (m) | 39 (7–72) | 23 (6–37) | |
| Median PFS (m) | 12 | N.R. | 0.01 |
| Median OS (m) | 39 | N.R. | 0.01 |
M: month, MPV: methotrexate + procarbazine + vincristine, MTX: methotrexate, N.R.: not reached, OS: overall survival, PFS: progression-free survival.